CardiArc Inc. said it recently gained additional Notices of Allowance from the U.S. Patent Office bringing its patents issued or pending to 30 surrounding its ultra-compact CardiArc SPECT system. The system, approved for marketing by the FDA in January, provides images of heart blood flow with up to 3 times the clarity of other units and up to 20 times more quickly, the company says. The unit is on display this week at the Society of Nuclear Medicine Annual Meeting in San Diego.
The company said it is in discussions with several manufacturers regarding application of its FOVea technology – which can be used with virtually any planar or SPECT system to “dramatically” expand its field of view with only minimal modifications – beyond the CardiArc system.
CardiArc also has a new COO, John Heinrich, PhD. He is charged with marketing, field service, technical suppose and clinical applications, as well as managing the company’s manufacturing relationships. Heinrich has 25 years of experience in management of healthcare technology, including positions with Meretek Diagnostics, Otsuka Electronics, Summit World Trade, Technomed and Technicare.